China Resources Double-Crane Pharmaceutical Co Ltd Total Liabilities

Latest as of September 2025: CN¥4.85 Billion CNY ≈ $710.14 Million USD

China Resources Double-Crane Pharmaceutical Co Ltd total liabilities. Based on the latest financial reports, China Resources Double-Crane Pharmaceutical Co Ltd (600062) has total liabilities worth CN¥4.85 Billion CNY (≈ $710.14 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check China Resources Double-Crane Pharmaceuti (600062) asset resilience to evaluate the company's liquid asset resilience ratio.

Total Liabilities of China Resources Double-Crane Pharmaceutical Co Ltd (1994–2024)

Total liabilities of China Resources Double-Crane Pharmaceutical Co Ltd from 1994 to 2024. This chart illustrates how China Resources Double-Crane Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of China Resources Double-Crane Pharmaceuti to see how much of total assets are deployed in long-term investments.

China Resources Double-Crane Pharmaceutical Co Ltd Competitors by Total Liabilities

The table below lists competitors of China Resources Double-Crane Pharmaceutical Co Ltd ranked by their total liabilities.

Company Country Total Liabilities
Shanghai Huace Navigation Technology Ltd
SHE:300627
China CN¥1.64 Billion
Hpsp Co Ltd
KQ:403870
Korea ₩99.80 Billion
Zhejiang Provincial New Energy Investment Group Co Ltd
SHG:600032
China CN¥40.16 Billion
Proximus NV
BR:PROX
Belgium €8.79 Billion
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
China CN¥9.50 Billion
Fujian Newland Computer Co Ltd
SHE:000997
China CN¥7.76 Billion
Civitas Resources Inc
NYSE:CIVI
USA $8.43 Billion
Mister Car Wash, Inc. Common Stock
NASDAQ:MCW
USA $2.03 Billion

Liability Composition Analysis (1994–2024)

This chart breaks down China Resources Double-Crane Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see China Resources Double-Crane Pharmaceuti (600062) total assets.

Liquidity & Leverage Metrics

China Resources Double-Crane Pharmaceutical Co Ltd Total Liabilities Ratios Explained

China Resources Double-Crane Pharmaceutical Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 2.25 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.43 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.29 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how China Resources Double-Crane Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for China Resources Double-Crane Pharmaceutical Co Ltd (1994–2024)

The table below shows the annual total liabilities of China Resources Double-Crane Pharmaceutical Co Ltd from 1994 to 2024.

Year Total Liabilities Change
2024-12-31 CN¥5.57 Billion
≈ $815.69 Million
+53.09%
2023-12-31 CN¥3.64 Billion
≈ $532.82 Million
-2.98%
2022-12-31 CN¥3.75 Billion
≈ $549.17 Million
+17.30%
2021-12-31 CN¥3.20 Billion
≈ $468.19 Million
+5.26%
2020-12-31 CN¥3.04 Billion
≈ $444.77 Million
+16.89%
2019-12-31 CN¥2.60 Billion
≈ $380.51 Million
+8.46%
2018-12-31 CN¥2.40 Billion
≈ $350.84 Million
+50.85%
2017-12-31 CN¥1.59 Billion
≈ $232.57 Million
+32.11%
2016-12-31 CN¥1.20 Billion
≈ $176.04 Million
-9.49%
2015-12-31 CN¥1.33 Billion
≈ $194.50 Million
+42.17%
2014-12-31 CN¥934.93 Million
≈ $136.81 Million
-18.32%
2013-12-31 CN¥1.14 Billion
≈ $167.50 Million
-36.44%
2012-12-31 CN¥1.80 Billion
≈ $263.55 Million
+3.89%
2011-12-31 CN¥1.73 Billion
≈ $253.69 Million
+35.49%
2010-12-31 CN¥1.28 Billion
≈ $187.24 Million
+8.24%
2009-12-31 CN¥1.18 Billion
≈ $172.99 Million
+5.69%
2008-12-31 CN¥1.12 Billion
≈ $163.68 Million
-14.53%
2007-12-31 CN¥1.31 Billion
≈ $191.52 Million
+3.53%
2006-12-31 CN¥1.26 Billion
≈ $184.98 Million
-32.55%
2005-12-31 CN¥1.87 Billion
≈ $274.23 Million
-18.45%
2004-12-31 CN¥2.30 Billion
≈ $336.26 Million
-9.57%
2003-12-31 CN¥2.54 Billion
≈ $371.86 Million
+26.33%
2002-12-31 CN¥2.01 Billion
≈ $294.35 Million
+60.12%
2001-12-31 CN¥1.26 Billion
≈ $183.83 Million
+99.76%
2000-12-31 CN¥628.89 Million
≈ $92.03 Million
+32.79%
1999-12-31 CN¥473.60 Million
≈ $69.30 Million
+137.31%
1998-12-31 CN¥199.57 Million
≈ $29.20 Million
+96.08%
1997-12-31 CN¥101.78 Million
≈ $14.89 Million
+109.89%
1996-12-31 CN¥48.49 Million
≈ $7.10 Million
+66.25%
1995-12-31 CN¥29.17 Million
≈ $4.27 Million
-19.92%
1994-12-31 CN¥36.42 Million
≈ $5.33 Million
--

About China Resources Double-Crane Pharmaceutical Co Ltd

SHG:600062 China Drug Manufacturers - Specialty & Generic
Market Cap
$2.34 Billion
CN¥15.99 Billion CNY
Market Cap Rank
#5424 Global
#897 in China
Share Price
CN¥15.39
Change (1 day)
+1.45%
52-Week Range
CN¥15.17 - CN¥19.70
All Time High
CN¥33.06
About

China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in the People's Republic of China. The company offers pharmaceutical products for blood pressure, blood sugar, injection, lipid-lowering, pediatrics, nephrology, API, pharmaceutical, psychiatry/neurology, anticoagulation, oncology, women's health, anesthesia, and analgesia. The company was founded in 1939 an… Read more